Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Arcturus Therapeutics Holdings (ARCT) EBIT Margin (2018 - 2025)

Historic EBIT Margin for Arcturus Therapeutics Holdings (ARCT) over the last 8 years, with Q3 2025 value amounting to 96.27%.

  • Arcturus Therapeutics Holdings' EBIT Margin fell 705100.0% to 96.27% in Q3 2025 from the same period last year, while for Sep 2025 it was 80.27%, marking a year-over-year decrease of 300600.0%. This contributed to the annual value of 62.81% for FY2024, which is 159300.0% down from last year.
  • Arcturus Therapeutics Holdings' EBIT Margin amounted to 96.27% in Q3 2025, which was down 705100.0% from 41.04% recorded in Q2 2025.
  • In the past 5 years, Arcturus Therapeutics Holdings' EBIT Margin ranged from a high of 75.77% in Q4 2022 and a low of 2711.14% during Q1 2021
  • Its 5-year average for EBIT Margin is 557.64%, with a median of 81.53% in 2022.
  • As far as peak fluctuations go, Arcturus Therapeutics Holdings' EBIT Margin plummeted by -23535500bps in 2021, and later soared by 26031300bps in 2022.
  • Quarter analysis of 5 years shows Arcturus Therapeutics Holdings' EBIT Margin stood at 649.72% in 2021, then surged by 112bps to 75.77% in 2022, then tumbled by -178bps to 59.22% in 2023, then crashed by -148bps to 146.68% in 2024, then skyrocketed by 34bps to 96.27% in 2025.
  • Its last three reported values are 96.27% in Q3 2025, 41.04% for Q2 2025, and 57.27% during Q1 2025.